http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Poseida Therapeutics (PSTX) Announces FDA Clearance of Investigational NDA for P-CD19CD20-ALLO1, an Allogeneic Dual CAR-T Cell Therapy for B-Cell Malignancies
-
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-CD19CD20-ALLO1, an Allogeneic Dual CAR-T Cell Therapy for B-Cell Malignancies
-
Poseida Therapeutics to Join Russell 3000® and Russell 2000® Indexes
-
Poseida Therapeutics Announces Virtual 2023 Annual Meeting of Stockholders
-
Poseida Therapeutics to Present at Stifel 2023 Tailoring Genes: Genetic Medicines Day
-
Poseida Therapeutics to Present at 31st Congress of the International Society on Thrombosis and Haemostasis
-
Poseida Therapeutics Presents Encouraging Preclinical Data Across its Gene Therapy Programs at the American Society for Gene and Cell Therapy 2023 Annual Meeting
-
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2023
-
Poseida Therapeutics Announces Multiple Presentations at the American Society of Gene and Cell Therapy 26th Annual Meeting
-
Poseida Therapeutics to Present at BofA Securities 2023 Health Care Conference
-
Poseida Therapeutics (PSTX) Appoints Rafael G. Amado to its Board
-
Poseida Therapeutics Appoints Rafael G. Amado, M.D., to Board of Directors
-
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Poseida Therapeutics Appoints Kristin Yarema, Ph.D., as President, Cell Therapy
-
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2022
-
Poseida Therapeutics Appoints Five New Members to Its Gene Therapy Scientific Advisory Board
-
Poseida Therapeutics Hosts Third Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations
-
Poseida Therapeutics to Present at H.C. Wainwright Cell Therapy Virtual Conference
-
Poseida Therapeutics to Host Third Annual Virtual R&D Day on February 22, 2023
-
Poseida Therapeutics (PSTX) Announces Board Changes
-
Poseida Therapeutics Announces Board Change
-
Poseida Therapeutics Presents Preclinical Data from P-FVIII-101 Gene Therapy for Hemophilia A at the 64th ASH Annual Meeting & Exposition
-
Poseida Therapeutics (PSTX) to Present Early Phase 1 Trial Data of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at ESMO I-O
-
Poseida Therapeutics to Present Early Data from Phase 1 Trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at ESMO Immuno-Oncology 2022 Annual Congress
-
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2022
-
Poseida Therapeutics to Present at Two Upcoming Investor Conferences
-
Poseida Therapeutics Announces Oral Presentation Highlighting P-FVIII-101 Gene Therapy at the 64th ASH Annual Meeting & Exposition
-
Poseida Therapeutics to Present at the ESMO Immuno-Oncology 2022 Annual Congress
-
Poseida Therapeutics to Present Trial in Progress Poster for Phase 1 P-MUC1C-ALLO1 Study at the Society for Immunotherapy of Cancer Annual Meeting
-
Poseida Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
-
Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2022
-
Poseida Therapeutics (PSTX) Announces Pact with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies
-
Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies
-
Renowned Geneticist to Chair Poseida Therapeutics Gene Therapy Scientific Advisory Board
-
Poseida Therapeutics (PSTX) Announces Publication Highlighting Potential of Cas-CLOVER™ as an Efficient and Robust Gene Editing System for Developing Allogeneic CAR-T Products
-
Poseida Therapeutics Announces Publication Highlighting Potential of Cas-CLOVER™ as an Efficient and Robust Gene Editing System for Developing Allogeneic CAR-T Products
-
Poseida Therapeutics Announces Virtual 2022 Annual Meeting of Stockholders
-
Poseida Therapeutics (PSTX) Appoints Charles M. Baum to its Board
-
Poseida Therapeutics Appoints Charles M. Baum, M.D., Ph.D., to Board of Directors
-
Poseida Therapeutics Presents Encouraging Preclinical Data Highlighting P-ckit-ALLO1 at the ASGCT 2022 Annual Meeting
-
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2022
-
Poseida Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual Meeting
-
Poseida Therapeutics to Present at BofA Securities 2022 Healthcare Conference
-
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2021
-
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Poseida Therapeutics Hosts Second Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations
-
Poseida Therapeutics Appoints Brent Warner as President, Gene Therapy
-
Poseida Therapeutics (PSTX) to Present Interim Results from Phase 1 Trial of P-PSMA-101 at ASCO Genitourinary Cancers Symposium
-
Poseida Therapeutics to Present Interim Results from Phase 1 Trial of P-PSMA-101 at ASCO Genitourinary Cancers Symposium
-
Poseida Therapeutics to Host Virtual R&D Day on February 23, 2022
